Lilly Will Test Obesity Drugs on Addiction, CEO Says

The transcript discusses the development of drugs in the obesity and metabolic health space, highlighting tirzepatide and other pipeline projects. It explores expanding drug applications to areas like cardiovascular health, diabetes, and anti-inflammatory conditions. The conversation also covers the company's stock buyback strategy and significant investments in R&D, emphasizing their commitment to innovation and investor returns.

What are 'antihedonics' and how are they related to the discussed medicines?

What future studies does the speaker mention regarding the use of their medicines?